[1]段 珊,彭 旷△,王卫忠,等.慢性阻塞性肺疾病急性加重期患者血清补体C5a水平及其与肺功能、IL-6、CRP水平相关性研究*[J].陕西医学杂志,2020,49(11):1444-1447.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.019]
　DUAN Shan,PENG Kuang,WANG Weizhong,et al.The levels of serum C5a and its association with pulmonary function,IL-6 and CRP levels in patients with acute exacerbation of chronic obstructive pulmonary disease[J].,2020,49(11):1444-1447.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.019]
点击复制

慢性阻塞性肺疾病急性加重期患者血清补体C5a水平及其与肺功能、IL-6、CRP水平相关性研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年11期
页码:
1444-1447
栏目:
临床研究
出版日期:
2020-11-05

文章信息/Info

Title:
The levels of serum C5a and its association with pulmonary function,IL-6 and CRP levels in patients with acute exacerbation of chronic obstructive pulmonary disease
作者:
段 珊; 彭 旷△; 王卫忠; 龙小平; 何菁子
南华大学附属第一医院呼吸内科(衡阳 421001)
Author(s):
DUAN Shan; PENG Kuang; WANG Weizhong; et al.
Department of Respiratory Medicine,the First Affiliated Hospital of South China University(Hengyang 421001)
关键词:
补体C5a;  慢性阻塞性肺疾病;  白介素6;  C反应蛋白;  肺功能
Keywords:
Complement C5a;  Chronic obstructive pulmonary disease;  Interleukin 6;  C reactive protein;  Lung function
分类号:
R563.9
DOI:
DOI:10.3969/j.issn.1000-7377.2020.11.019
文献标志码:
A
摘要:
目的:探讨慢性阻塞性肺疾病急性加重期(AECOPD)患者血清补体C5a水平及其与肺功能、IL-6及CRP水平的相关性。方法:选取39例AECOPD患者,根据治疗前动脉血二氧化碳分压(PaCO2)水平分为PaCO2升高组与PaCO2正常组。另选取11例健康体检者作为正常对照组。检测治疗前AECOPD患者血清补体C5a、白介素6(IL-6)、C反应蛋白(CRP)及PaCO2,记录肺功能指标(FEV1%、FVC%)、体质量指数(BMI)及吸烟指数。检测正常对照组血清补体C5a水平。采用Pearson法分析各指标的相关性。结果:AECOPD组患者血清补体C5a水平明显高于正常对照组(P<0.01)。PaCO2升高组补体C5a水平明显高于PaCO2正常组(P<0.01),但两组中IL-6、CRP水平无统计学差异(P>0.05)。AECOPD组补体C5a水平与FEV1%、FVC%呈负相关(均P<0.01),但与IL-6、CRP、BMI及吸烟指数无明显相关性(均P >0.05)。结论:AECOPD患者血清补体C5a水平与肺功能有明显相关性,COPD患者CO2潴留时,补体C5a水平明显增高。
Abstract:
Objective:To investigate the levels of serum C5a and its association with pulmonary function,IL-6 and CRP levels in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:39 patients with AECOPD were divided into PaCO2 elevated group and PaCO2 normal group according to PaCO2 level before treatment.Another 11 healthy people were selected as normal control group.The serum levels of C5a,IL-6,CRP and PaCO2 were measured before treatment.Pulmonary function indexes(FEV1%,FVC%),body mass index(BMI)and smoking index were recorded.The serum level of C5a was detected in normal control group.Pearson method was used to analyze the correlation of each index.Results:The serum C5a level in AECOPD group was significantly higher than that in normal control group(P<0.01).The level of C5a in PaCO2 elevated group was significantly higher than that in PaCO2 normal group(P<0.01),but there was no significant difference in the levels of IL-6 and CRP between the two groups(P>0.05).The level of C5a was negatively correlated with FEV1% and FVC% in AECOPD group(all P<0.01),but not with IL-6,CRP,BMI and smoking index(all P>0.05).Conclusion:Serum C5a is associated with lung function of patients with AECOPD.Moreover,serum C5a is higher when the patients have carbon dioxide retention.

参考文献/References:

[1] 陈辅萍.慢性阻塞性肺疾病并发感染性肺炎危险因素分析[J].陕西医学杂志,2020,49(1):102-104.
[2] 刘新平,王展儒.理肺化痰通脉方治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2020,41(4):484-486.
[3] 周志强,曲建卫,咸本松,等.慢性阻塞性肺疾病患者接种肺炎球菌疫苗疗效的Meta分析[J].中华全科医学,2018,16(9):1562-1565,1574.
[4] 刘鹏军,雷 荣,刘宏伟.伴肺动脉高压的慢性阻塞性肺疾病患者的血清炎性因子水平变化及意义[J].中国急救复苏与灾害医学杂志,2020,15(3):315-318.
[5] 申永春,富国强.2017年慢性阻塞性肺疾病全球创议更新解读[J].中国实用内科杂志,2017,37(2):132-135.
[6] Allinson JP,Hardy R,Donaldson GC,et al.Combined impact of smoking and early-life exposures on adult lung function trajectories[J].Am J Respir Crit Care Med,2017,196(8):1021-1030.
[7] Marc MM,Korosec P,Kosnik M,et al.Complement actors C3a,C4a,and C5a in chronic obstructive pulmonary disease and asthma[J].Am J Respir Cell Mol Biol,2004,31(2):216-219.
[8] Khan MA.Inflammation signals airway smooth muscle cell proliferation in asthma pathogenesis[J].Multidiscip Respir Med,2013,8(1):11.
[9] Khan MA,Nicolls MR,Surguladze B,et al.Complement components as potential therapeutic targets for asthma treatment[J].Respir Med,2014,108(4):543-549.
[10] Stimler NP,Hugli TE,Bloor CM.Pulmonary injury induced by C3a and C5a anaphylatoxins[J].Am J Pathol,1980,100(2):327-348.
[11] Khameneh HJ,Ho AW,Laudisi F,et al.C5a regulates IL-1beta production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis[J].Front Pharmacol,2017,8:10.
[12] Schroder K,Tschopp J.The inflammasomes[J].Cell,2010,140(6):821-832.
[13] Kristan SS.Blood specimen biomarkers of inflammation,matrix degradation,angiogenesis,and cardiac involvement:a future useful tool in assessing clinical outcomes of COPD patients in clinical practice[J].Arch Immunol Ther Exp(Warsz),2013,61(6):469-481.
[14] Khan MA,Assiri AM,Broering DC.Complement mediators:key regulators of airway tissue remodeling in asthma[J].J Transl Med,2015,13:272.
[15] Marc MM,Kristan SS,Rozman A,et al.Complement factor C5a in acute exacerbation of chronic obstructive pulmonary disease[J].Scand J Immunol,2010,71(5):386-391.
[16] Westwood JP,Mackay AJ,Donaldson G,et al.The role of complement activation in COPD exacerbation recovery[J].ERJ Open Res,2016,2(4):2011-2016.
[17] Dahl M,Vestbo J,Lange P,et al.C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2007,175(3):250-255.
[18] 白翠林.hsCRP、PCT检测在老年慢性阻塞性肺疾病急性加重期的临床应用[J].陕西医学杂志,2015,44(7):925-926.
[19] 王成斌.慢性阻塞性肺疾病急性加重期血清降钙素原与C反应蛋白的测定及临床意义[J].陕西医学杂志,2016,45(5):617-618.
[20] Kelly E,Owen CA,Pinto-Plata V,et al.The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease[J].Expert Rev Respir Med,2013,7(1):57-64.

相似文献/References:

[1]李 赟.系统性红斑狼疮患者血清补体C5a和红细胞沉降率检测及临床意义[J].陕西医学杂志,2020,49(1):52.
　LI Yun..Expression of serum C5a and ESR in patients with systemic lupus erythematosus and its clinical significance[J].,2020,49(11):52.
[2]肇 阳,卜 伟,温有锋△.矽肺与人体体成分关系临床研究*[J].陕西医学杂志,2020,49(4):415.
　ZHAO Yang,BU Wei,WEN Youfeng..Clinical research on relationship between silicosis and human body composition[J].,2020,49(11):415.
[3]陈 芳,杜锦辉△.机械通气辅以纳洛酮治疗慢性阻塞性肺疾病并呼吸衰竭疗效研究[J].陕西医学杂志,2020,49(4):466.
　CHEN Fang,DU Jinhui..Effect of mechanical ventilation combined with naloxone on operation related indexes and therapeutic effect in COPD patients with respiratory failure[J].,2020,49(11):466.
[4]杜锦辉,陈 芳△.BiPAP无创呼吸机治疗慢性阻塞性肺疾病并Ⅱ型呼吸衰竭50例临床研究*[J].陕西医学杂志,2020,49(7):824.[doi:DOI:10.3969/j.issn.10007377.2020.07.015]
　DU Jinhui,CHEN Fang..BiPAP non-invasive ventilator in treatment of COPD patients with type Ⅱ respiratory failure:a clinical study of 50 cases[J].,2020,49(11):824.[doi:DOI:10.3969/j.issn.10007377.2020.07.015]
[5]杨文林,倪红燕,王海峰.经鼻高流量氧疗序贯治疗慢性阻塞性肺疾病合并呼吸衰竭临床研究*[J].陕西医学杂志,2020,49(10):1280.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.021]
[6]康文玥,杨淑梅,遆嬿羽,等.嗜酸性粒细胞与慢性阻塞性肺疾病相关性研究进展[J].陕西医学杂志,2021,50(8):1034.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.033]
[7]马俊彦,魏永梅,王登本,等.茚达特罗/格隆溴铵和长效β2受体激动剂/长效M受体阻滞剂治疗慢性阻塞性肺疾病稳定期有效性及不良反应发生Meta分析[J].陕西医学杂志,2021,50(10):1309.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.034]
[8]康 睿,张亚琼.阿比多尔对慢性阻塞性肺疾病大鼠气道炎症及气道黏液高分泌影响的实验研究[J].陕西医学杂志,2022,51(4):391.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.002]
　KANG Rui,ZHANG Yaqiong.Effect of abidol on airway inflammation and airway mucus hypersecretion in rats with chronic obstructive pulmonary disease[J].,2022,51(11):391.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.002]
[9]张惠民,杜旭升,范亚莉,等.重症肺炎120例多重耐药菌感染情况及影响因素分析[J].陕西医学杂志,2022,51(7):835.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.016]
　ZHANG Huimin,DU Xusheng,FAN Yali,et al.Situation and influencing factors of multidrug-resistant organism infection in 120 patients with severe pneumonia[J].,2022,51(11):835.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.016]
[10]窦 飞,王国清,宋东虎,等.CT评估慢性阻塞性肺疾病肺功能临床研究进展[J].陕西医学杂志,2023,52(7):942.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.038]
　DOU Fei,WANG Guoqing,SONG Donghu,et al.Clinical research progress in CT evaluation of pulmonary function in chronic obstructive pulmonary disease[J].,2023,52(11):942.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.038]

备注/Memo

备注/Memo:
*湖南省自然科学基金资助项目(2017JJ3269)；湖南省教育厅科学研究项目(19C1574)
更新日期/Last Update: 2020-11-05